GlassScriptPhysician profile
Michelle Han
NPI 1578044046
$2,834.71
in general payments reported to CMS, 2019-2025
28 companies · $44.46 in 2025
The $44.46 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $678 · 2022: $800 · 2023: $1,048 · 2024: $264 · 2025: $44.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.89 | 2021-2024 | |
| Novo Nordisk INC | $330.85 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $280.90 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Biohaven Pharmaceuticals, INC. | $209.57 | 2021 | |
| Dexcom, INC. | $132.44 | 2022-2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $123.01 | 2022-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $118.03 | 2021-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $114.74 | 2022-2023 | |
| Glaxosmithkline, LLC. | $114.53 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $113.62 | 2021-2022 | |
| Pfizer INC. | $95.15 | 2022-2023 | |
| Exact Sciences Corporation | $64.07 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $51.79 | 2022-2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $49.99 | 2022 | |
| Astellas Pharma US INC | $44.46 | 2025 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $43.09 | 2021-2023 | Contrave |
| Astrazeneca Pharmaceuticals LP | $40.39 | 2021-2023 | Breztri |
| Amarin Pharma, INC. | $38.55 | 2021 | |
| Jazz Pharmaceuticals INC. | $37.88 | 2021-2022 | |
| Neos Therapeutics, LP | $31.62 | 2021 | |
| Coloplast Corp | $30.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.80 | 2022 | |
| Galt Pharmaceuticals, LLC | $23.76 | 2023 | Orphengesic Forte |
| Otsuka America Pharmaceutical, INC. | $23.51 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $21.13 | 2022 | |
| Linus Health, INC. | $15.83 | 2022 | |
| Eisai INC. | $14.10 | 2021 | |
| Kyowa Kirin, INC. | $13.35 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.